With Pfizer’s revenue and share price slumping after the drugmaker skyrocketed to new heights during the pandemic, the ...

Health insurance companies are expected to pull back slightly from Medicare Advantage investing in 2025. Instead, Modern Healthcare reports, they will focus on Dual-Eligible Special Needs Plans, or ...

Pfizer CEO Albert Bourla reportedly is planning to meet with Starboard Value after the activist investor took a $1 billion ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

Shares of Pfizer (NYSE: PFE) have been stuck in the mud since December 2022, with its shares down more than 45% over that ...

Albert Bourla, the CEO of pharmaceutical company Pfizer ($PFE), plans to meet with activist investor Starboard Value in ...

--Pfizer's Chief Executive Albert Bourla plans to meet Starboard Value next week with at least one other director after the activist investor acquired a $1 billion stake in the healthcare company, the ...

In another blow to its $525 million buyout of ReViral, Pfizer has ended development of sisunatovir, an oral inhibitor ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Starboard has a roughly $1 billion stake in the drugmaker and approached former Pfizer CEO Ian Read and ex-CFO Frank D'Amelio ...

Is your company bracing for Milton or working to provide aid in anticipation of the storm? | Pfizer—which opened a global hub ...

The Roundhill Magnificent Seven ETF — which holds Big Tech stocks including Nvidia, Apple Inc., Microsoft Corp, Alphabet Inc.